2-propanol has been researched along with etoposide in 5 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 1 (20.00) | 18.2507 |
2000's | 1 (20.00) | 29.6817 |
2010's | 2 (40.00) | 24.3611 |
2020's | 1 (20.00) | 2.80 |
Authors | Studies |
---|---|
Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
Chen, JR; Chow, D; Shah, JC | 1 |
Leahey, A; Manquez, ME; Meadows, AT; Shields, CL; Shields, JA; Sun, H | 1 |
Patel, J; Shields, CL; Turaka, K | 1 |
Huang, Z; Zhang, Y | 1 |
5 other study(ies) available for 2-propanol and etoposide
Article | Year |
---|---|
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Metastable polymorph of etoposide with higher dissolution rate.
Topics: 2-Propanol; Antineoplastic Agents, Phytogenic; Calorimetry, Differential Scanning; Chemistry, Pharmaceutical; Crystallization; Etoposide; Microscopy, Polarization; Solubility; Solvents; Spectrophotometry, Infrared | 1999 |
Resolution of iris neovascularization following chemoreduction of advanced retinoblastoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Etoposide; Female; Fluorescein Angiography; Glaucoma, Neovascular; Humans; Infant; Iris; Neovascularization, Pathologic; Retinal Neoplasms; Retinoblastoma; Vincristine | 2006 |
Resolution of iris neovascularization following chemoreduction of retinoblastoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Child, Preschool; Etoposide; Female; Humans; Iris; Neovascularization, Pathologic; Retinal Neoplasms; Retinoblastoma; Treatment Outcome; Ultrasonography; Vincristine; Visual Acuity | 2010 |
Iris metastasis as resistance mechanism to atezolizumab, carboplatin, and etoposide but responds to additional irinotecan and anlotinib in a small cell lung cancer patient.
Topics: Antineoplastic Combined Chemotherapy Protocols; Blindness; Carboplatin; Carcinoma, Small Cell; Etoposide; Female; Humans; Irinotecan; Iris; Lung Neoplasms; Small Cell Lung Carcinoma | 2023 |